<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Opko Health Inc — News on 6ix</title>
<link>https://6ix.com/company/opko-health-inc</link>
<description>Latest news and press releases for Opko Health Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/opko-health-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a6ec78dffbe2df10bb7c.webp</url>
<title>Opko Health Inc</title>
<link>https://6ix.com/company/opko-health-inc</link>
</image>
<item>
<title>OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-reports-first-quarter-2026-business-highlights-and-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-reports-first-quarter-2026-business-highlights-and-financial-results</guid>
<pubDate>Tue, 28 Apr 2026 20:05:00 GMT</pubDate>
<description>Conference call begins at 4:30 p.m. Eastern time todayMIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first quarter of 2026 and recent weeks included the following: Initiated and completed first dose cohort of MDX2301 Phase 1 clinical trial for the prevention of COVID-19. MDX2301 is a tetravalent bispecific antibody that neutralizes all known variants</description>
</item>
<item>
<title>OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-healths-modex-therapeutics-begins-clinical-trial-of-tetraspecific-antibody-for-treatment-of-b-cell-lymphomas</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-healths-modex-therapeutics-begins-clinical-trial-of-tetraspecific-antibody-for-treatment-of-b-cell-lymphomas</guid>
<pubDate>Wed, 22 Apr 2026 12:00:00 GMT</pubDate>
<description>Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of Hematology (ASH) Annual Meeting and ESMO Targeted Anticancer Therapies Congress 2026 WESTON, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced the dosing of patients with its first-in-class tetraspecific T-cell engager, MDX2003, for relap</description>
</item>
<item>
<title>OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-to-report-first-quarter-2026-financial-results-on-april-28-2026</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-to-report-first-quarter-2026-financial-results-on-april-28-2026</guid>
<pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
<description>MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on Tuesday, April 28, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 28th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages par</description>
</item>
<item>
<title>OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-healths-modex-therapeutics-initiates-clinical-trial-of-mdx2301-for-the-prevention-of-covid-19</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-healths-modex-therapeutics-initiates-clinical-trial-of-mdx2301-for-the-prevention-of-covid-19</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>Subjects dosed in Phase 1 study evaluating safety and tolerability of a first-in-class multispecific antibody WESTON, Mass., April 08, 2026 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>OPKO Health to Participate in the Jefferies Biotech on the Beach Summit</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-to-participate-in-the-jefferies-biotech-on-the-beach-summit</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-to-participate-in-the-jefferies-biotech-on-the-beach-summit</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the</description>
</item>
<item>
<title>OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-reports-fourth-quarter-2025-business-highlights-and-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-reports-fourth-quarter-2025-business-highlights-and-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
<description>Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies</description>
</item>
<item>
<title>OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-report-fourth-quarter-130000028</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-report-fourth-quarter-130000028</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages par</description>
</item>
<item>
<title>OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-and-entera-bio-expand-partnership-advance-first-class-oral-long-acting-0</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-and-entera-bio-expand-partnership-advance-first-class-oral-long-acting-0</guid>
<pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
<description>This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies</description>
</item>
<item>
<title>OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-participate-44th-annual-jp-morgan-healthcare-conference-2026-01-06</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-participate-44th-annual-jp-morgan-healthcare-conference-2026-01-06</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan</description>
</item>
<item>
<title>OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-participate-piper-sandler-37th-annual-healthcare-conference-2025-11-19</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-participate-piper-sandler-37th-annual-healthcare-conference-2025-11-19</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th</description>
</item>
<item>
<title>NextPlat Reports Third Quarter 2025 Results</title>
<link>https://6ix.com/company/opko-health-inc/news/nextplat-reports-third-quarter-2025-results-2025-11-13</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/nextplat-reports-third-quarter-2025-results-2025-11-13</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>Company Reports $13.8M in Q3 Revenue as Refocusing and Cost Cutting Initiatives Drive Improved Late Quarter Performance with Accelerated Sequential</description>
</item>
<item>
<title>Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/opko-health-inc/news/cocrystal-pharma-insiders-purchase-dollar103-million-in-private-placement-priced-at-the-market-under-nasdaq-rules</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/cocrystal-pharma-insiders-purchase-dollar103-million-in-private-placement-priced-at-the-market-under-nasdaq-rules</guid>
<pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
<description>Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (the “Company” or “Cocrystal”) announces the completion of a private placement of units priced at-the-market under Nasdaq rules with 743,024 shares of its common stock at a purchase price of $1.39 per unit for proceeds of $1.03 million and unregistered wa</description>
</item>
<item>
<title>OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-reports-third-quarter-2025-business-highlights-and-financial-results-2025</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-reports-third-quarter-2025-business-highlights-and-financial-results-2025</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>Conference call begins at 4:30 p.m. Eastern time today MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business</description>
</item>
<item>
<title>OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-healths-modex-therapeutics-enters-research-collaboration-regeneron-develop</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-healths-modex-therapeutics-enters-research-collaboration-regeneron-develop</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple</description>
</item>
<item>
<title>OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-healths-modex-therapeutics-begins-clinical-trial-mdx2004-treatment-advanced</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-healths-modex-therapeutics-begins-clinical-trial-mdx2004-treatment-advanced</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster</description>
</item>
<item>
<title>OPKO Health to Report Third Quarter 2025 Financial Results on October 29</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-report-third-quarter-2025-financial-results-october-29-2025-10-22</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-report-third-quarter-2025-financial-results-october-29-2025-10-22</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended</description>
</item>
<item>
<title>Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses</title>
<link>https://6ix.com/company/opko-health-inc/news/labcorp-completes-acquisition-of-select-assets-of-bioreference-healths-innovative-oncology-and-related-clinical-testing-services-businesses</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/labcorp-completes-acquisition-of-select-assets-of-bioreference-healths-innovative-oncology-and-related-clinical-testing-services-businesses</guid>
<pubDate>Mon, 15 Sep 2025 12:30:00 GMT</pubDate>
<description>Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today the completion of Labcorp's acquisition of select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.</description>
</item>
<item>
<title>OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-reports-second-quarter-2025-business-highlights-and-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-reports-second-quarter-2025-business-highlights-and-financial-results</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights</description>
</item>
<item>
<title>OPKO Health to Report Second Quarter 2025 Financial Results on July 31</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-report-second-quarter-2025-financial-results-july-31-2025-07-24</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-report-second-quarter-2025-financial-results-july-31-2025-07-24</guid>
<pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
<description>MIAMI, July 24, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended</description>
</item>
<item>
<title>OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress</title>
<link>https://6ix.com/company/opko-health-inc/news/opko-health-and-entera-bio-announce-abstract-pk-pd-oral-glp-2-tablet-treatment-short</link>
<guid isPermaLink="true">https://6ix.com/company/opko-health-inc/news/opko-health-and-entera-bio-announce-abstract-pk-pd-oral-glp-2-tablet-treatment-short</guid>
<pubDate>Tue, 08 Jul 2025 04:00:00 GMT</pubDate>
<description>MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced</description>
</item>
</channel>
</rss>